Dr. Barry Dworkin

Study offers new insight into possible treatment for Lou Gehrig's disease (ALS)

Madely Health Headlines Commentary for June 13, 2014

[display_podcast]

Source:

Findings point toward one of first therapies for Lou Gehrig’s disease

Reference:

Oral Treatment with CuII(atsm) Increases Mutant SOD1 In Vivo but Protects Motor Neurons and Improves the Phenotype of a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis. Journal of Neuroscience, 2014; 34 (23): 8021 DOI: 10.1523/JNEUROSCI.4196-13.2014

Related posts:

  1. Former US ambassador Cellucci diagnosed with ALS
  2. Alzheimer drug trial failure offers much to learn and should not be seen as a dead end
  3. Excellent clinical science produces possible long-term remission for rapidly progessing MS
  4. Unpublished non-peer-reviewed short-term study on possible COVID-19-induced cognitive decline used self-reported unverified data with no baseline controls or knowledge of the patients cognitive status prior to infection.